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Charcot–Marie–Tooth disease (CMT) comprises a family of clinically and genetically very heterogeneous
hereditary peripheral neuropathies and is one of the most common inherited neurological disorders. We
have generated a mouse model for CMT type 4B1 using embryonic stem cell technology. To this end, we
introduced a stop codon into the Mtmr2 locus within exon 9, at the position encoding amino acid 276 of
the MTMR2 protein (E276X). Concomitantly, we have deleted the chromosomal region immediately down-
stream of the stop codon up to within exon 13. The resulting allele closely mimics the mutation found in a
Saudi Arabian CMT4B1 patient. Animals homozygous for the mutation showed various degrees of complex
myelin infoldings and outfoldings exclusively in peripheral nerves, in agreement with CMT4B1 genetics and
pathology. Mainly, paranodal regions of the myelin sheath were affected, with a high degree of quantitative
and qualitative variability between individuals. This pathology was progressive with age, and axonal damage
was occasionally observed. Distal nerve regions were more affected than proximal parts, in line with the
distribution in CMT. However, we found no significant electrophysiological changes, even in aged
(16-month-old) mice, suggesting that myelin infoldings and outfoldings per se are not invariably associated
with detectable electrophysiological abnormalities. Our animal model provides a basis for future detailed
molecular and cellular studies on the underlying disease mechanisms in CMT4B1. Such an analysis will
reveal how the disease develops, in particular, the enigmatic myelin infoldings and outfoldings as well as
axonal damage, and provide mechanistic insights that may aid in the development of potential therapeutic
approaches.
INTRODUCTION
Charcot and Marie in France and Tooth in England described
the clinical features of hereditary motor and sensory neuropa-
thies in the late 19th century (reviewed in 1). Thus, this group
of disorders is referred to as Charcot–Marie–Tooth (CMT)
disease. With an estimated prevalence of 1:2500, CMT is one
of the major genetic diseases in clinical neuroscience. Main
features are slowly progressive distal and proximal muscle
weakness and atrophy. Using clinical, electrophysiological
and histological criteria, CMT has been divided into demyeli-
nating (CMT1, CMT3, CMT4) and axonal forms (CMT2).
Reduced nerve conduction velocity (NCV) and conduc-
tion failure due to primary segmental demyelination is
characteristic of demyelinating neuropathies. The myelin
deficit is followed by axonal degeneration leading to muscular
atrophy (2,3). Axonal forms of CMT are associated with
nearly normal NCV, but loss of myelinated fibers causes a
conduction failure in degenerated nerve fibers, resulting in a
reduction of the compound action potential amplitude.
In this case, the primary insult is thought to affect the axon
or neuron, eventually followed by secondary demyelina-
tion (4,5).
Initially, it was assumed that defects in Schwann cell-
specific proteins would result in demyelinating neuropathies,
whereas defects in neuron-specific proteins lead to axonal
forms of CMT. However, recent progress in identifying
the responsible disease genes and unraveling the complex
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interplay of Schwann cells and axons in peripheral nerves has
shown that primary and secondary effects can often not be
resolved with certainty (2). Both Schwann cells and neurons
may express a particular disease-causing gene, making simple
distinctions as to disease contributions by the different cell
types difficult.
The severe autosomal recessive CMT4B1 is caused by
mutations in myotubularin related protein-2 (MTMR2) (6–8)
including missense, nonsense, frameshift and exon-skipping
deletions. Disease onset is usually in early childhood, and
NCV is markedly reduced. Histological analysis of nerve
biopsies revealed characteristic focally folded myelin sheaths
and demyelination, although this pathologic feature is not
unique to CMT4B1 (9,10). Mtmr2 is expressed by both
neurons and Schwann cells, and their individual cellular con-
tributions to the phenotype are not yet clear (11,12). Recent
experimental data obtained by Schwann cell-specific disrup-
tion of Mtmr2 indicate a major role of this cell type (13).
MTMR2 is a member of the myotubularin family of
dual specific phosphatases. Myotubularin is the founding
member of the family, and mutations in the myotubularin
gene cause X-linked myotubular myopathy, one of the
severe congenital muscle diseases causing a ‘floppy infant
syndrome’ (14). On the basis of sequence and structural
analysis, all myotubularins contain characteristic domains:
a PH (pleckstrin-homology)/GRAM (glycosyltransferase,
Rab-like-GTPase activator and myotubularins) domain, a
phosphatase domain and a coiled-coil domain. In MTMR2,
a coiled-coil domain mediates dimerization, and, together
with the PH/GRAM domain which binds to phospha-
tidylinositol 3,5-bisphosphate [PI(3,5)P2] and PI(5)P, is
required for membrane targeting (15). MTMR2 also carries
a C-terminal PDZ (PSD-95/Dlg/ZO-1)-binding motif that
binds to disc-large 1/synapse-associated protein 97 (DLG1)/
(SAP97) (13). An interaction with neurofilament light chain
(NF-L) has also been reported (16).
Depending on the functionality of the phosphatase domain,
the myotubularins are divided into two subgroups: Those
family members with an intact phosphatase motif (Cys-X5-
Arg) form the group of active phosphatases, whereas some
myotubularins have modifications in the active site turning
them into inactive phosphatases. Intriguingly, mutations
affecting the inactive phosphatase MTMR13/SBF2 are associ-
ated with CMT4B2, a neuropathy that is clinically and patho-
logically indistinguishable from CMT4B1 (17,18). Active and
inactive myotubularins tend to physically interact with each
other (19–21) and recent evidence suggests that MTMR2
and MTMR13/SBF2 act as a similar functional pair in
myelinated peripheral nerves (22) (Berger et al., manuscript
in preparation).
Active myotubularins dephosphorylate both PI(3,5)P2 and
PI(3)P (11,23,24) by removing the phosphate group on the
D3 position. MTMR2 displays a higher activity toward
PI(3,5)P2 (11). The physiological significance of this obser-
vation is unclear, although it may be connected to the
membrane targeting of MTMR2 mediated by the coiled-coil
and PH/GRAM domains. MTMR2 mutations associated with
CMT4B1 lead to a loss or strong reduction of phosphatase
activity on both substrates, consistent with a crucial role in
the disease (11).
Recent reports based on appropriate animal models have
provided encouraging prospects for new strategies to amelio-
rate CMT (25–27). These promising developments underline
the value of animal models for our further understanding of
basic disease mechanisms, thereby contributing to the evalua-
tion of potential treatments (28). In this report, we describe the
generation and analysis of a new animal model of CMT4B1 as
a prerequisite for such approaches.
RESULTS
Disruption of Mtmr2
We designed a targeting vector for recombination in ES cells
to mimic the genetic situation in a CMT4B1 patient at the
MTMR2 locus (6). To achieve this goal, a stop codon was
introduced into exon 9 at the codon for amino acid 276,
which is within the phosphatase domain. In addition, the
region downstream of this mutation to within exon 13 was
replaced by an IRES-lacZ-tk-neo cassette (Fig. 1A). Southern
blot analysis of correctly targeted ES cells and genomic tail
DNA, derived from the resulting mutant mice, revealed the
expected diagnostic bands (Fig. 1B). Single integration was
further confirmed by a lacZ probe (Fig. 1B). Mutant mice
obtained from two independent ES cell clones were viable
and born with Mendelian frequency. An Mtmr2-derived tran-
script was readily detected in mutant mice, and, as expected,
immunohistochemical analysis on nerve sections suggested
that a truncated MTMR2 protein is still expressed by periph-
eral nerves of homozygous mutant mice (data not shown).
Unfortunately, reliable biochemical detection and analysis of
this putative protein was not successful with the available
reagents.
Mice homozygous for the mutant allele appeared outwardly
normal by visual inspection up to the age of 16 months, the
oldest stage analyzed. Occasionally, homozygous mutants
show an unusual but only mild clamping of the hind limbs
after prolonged suspension by the tail. No significant differ-
ences were found in gait and performance in the Rotarod test
or in grip strength (Fig. 1C). Heterozygous mice were indistin-
guishable from their wild-type (wt) littermates at all ages.
Altered myelin in homozygous Mtmr2 mutant mice
On the basis of the pathology described in peripheral nerves of
CMT4B1 patients, we started our analysis with this tissue. At
the age of 2 months, the morphology of mutant peripheral
nerves appeared grossly normal (Fig. 2A–C). However,
at higher magnification, we found abnormal Schwann cell–
axon units with redundant myelin loops arranged around
myelinated, usually large caliber axons, exclusively in
homozygous mutants (arrows and arrowhead in Fig. 2F).
Myelinated small caliber axons and non-myelinated axons
appeared unaffected.
Progression of myelin abnormalities
in Mtmr2 mutant mice
As demyelinating neuropathies follow a progressive time
course, we analyzed the focally redundant myelin at the age
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of 3 weeks and at 2, 4 and 6 months. At 3 weeks, some rare
affected myelin sheaths were already detectable in association
with large myelinated fibers in homozygous mutants (Fig. 3E).
At later stages, the number and complexity of affected
Schwann cell–axon units were increased, and small myeli-
nated fibers were also affected (Fig. 3E–H). We did not
observe obvious signs of demyelination and remyelination,
such as thin myelin sheaths associated with large axons or
onion bulb formation.
To quantify redundant myelin formation and its progression
with age, we determined the fraction of abnormal Schwann
cell–axon units in the pectineus nerve of wt and homozygous
mutant animals at 3 weeks and 6 months of age. Older mutants
tended to have more fibers affected with redundant myelin
loops than did younger mice. We also noted, however, a
high variability in the degree of pathology among individual
mutant mice at both ages (Fig. 4A). Furthermore, we com-
pared the axonal caliber in relation to myelin thickness in
the sciatic nerve of homozygous mutants versus wt mice,
but found no significant alterations (Fig. 4B).
Distal parts of peripheral nerves of Mtmr2 mutants are
more severely affected than proximal areas
Hereditary demyelinating neuropathies often more strongly
affect distal rather than proximal segments of peripheral
nerves (29). Although it has been speculated that this could
be due to impaired transport along the axon from the neuronal
cell body to the periphery (2), this hypothesis remains to
be confirmed. To examine whether distal nerves are more
affected than proximal segments also in our model, we ana-
lyzed peripheral nerves of 6-month-old homozygous mutants
at the root level and in distal nerve branches. Indeed, we
found more pronounced redundant myelin formation in distal
motor (gluteus) and sensory (saphenous) nerves compared
with the nerve roots (Fig. 5, compare A with C and B with D).
Motor and sensory branches did not differ significantly in the
severity of the myelin phenotype.
In CMT4B1 patients, the phenotype is restricted to the PNS
with no obvious defects in the CNS. In agreement, we found
no alterations in the optic nerve or in the spinal cord of
mutant mice (data not shown).
Structure of redundant myelin in Mtmr2
mutants is highly complex
We performed ultrastructural analyses to further characterize
the focally folded redundant myelin loops that are specific
hallmarks of Mtmr2 mutants and highly reminiscent of the
pathological features found in CMT4B1 (7). Figure 6A pre-
sents a collection of the different forms of abundant myelin
figures found in mutant nerves. In the most common for-
mation, one or several myelin loops were arranged around
a core-myelinated large caliber fiber (a). These myelin
loops contained axoplasma-like structures (Fig. 7) (data not
shown). Abnormal myelin occurred not only as loops but
also as finger-like elongations wrapped around the axon (b).
However, this appearance may also be due to a myelin loop
indented into the original axon. Comma-like extensions of
the core-myelinated axon were often observed, although
they are not specific to the mutant (c). In mutant nerves,
these extensions were often large in size and long enough
to surround aberrant myelin loops of the same Schwann
cell–axon unit (d). Redundant myelin loops were also found
Figure 1. Targeted disruption of Mtmr2. (A) Schematic depiction of the
Mtmr2 wt allele, targeting construct and mutated allele. Solid boxes represent
exons 6–15 of Mtmr2. After homologous recombination, a stop codon, indi-
cated by an asterisk, is inserted into exon 9 at the same position as described
for a CMT4B1 patient. The resulting premature translation termination leads
to a putative protein of 275 amino acids. Additionally, the IRES-lacZ-tk-neo
cassette replaces the genomic region from exon 9 to within exon 13, encoding
major parts of the PTP and SID motifs. Positions of XbaI (X) restriction sites
used for Southern blot analysis are indicated. Bars indicate the 50-external
probe and the lacZ probe. PCR primer pairs (arrowheads) W1 plus W2
(wt PCR) and K1 plus K2 (mutant PCR) were used for genotyping. Note
that introns and exons are not drawn to scale. (B) Southern blot analysis of
wt and recombined ES cells, and wt, heterozygous mutant (þ/m) and homo-
zygous mutant (m/m) mice. Genomic DNA isolated from ES cells or tail bio-
psies was digested with XbaI and hybridized with a radioactive probe. Because
of the insertion of an additional XbaI restriction site with the lacZ-tk-neo
cassette (see A), the mutant allele (m) gives a shorter 2.5 kb fragment com-
pared with the wt 4.4 kb fragment when probed with the 50-external probe.
The lacZ probe was used to confirm single integration. (C) A Rotarod test
was used to assess the motor activity of 9-month-old wt, Mtmr2 þ/m and
Mtmr2 m/m mice. Mice were tested four times per day every 2 h on four con-
secutive days. The time spent on the rotating rod versus the trial number was
plotted. Averages for eight mice per genotype are shown. No significant differ-
ences were observed. (D) The same mice as for (C) were used for grip strength
analysis. The y-axis shows the maximum weight the mice could hold in
relation to the body weight. There is no significant difference in the forelimb
grip strength of wt and Mtmr2 m/m mice.
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inside the axon (e) or inside another aberrant myelin loop (f).
Single loops were present but also multiple loops nested into
each other (e and f). Degenerating Schwann cell–axon units
(g) were seen only very rarely.
To gain further insights into the structure of the redundant
myelin, we analyzed teased fibers and longitudinal sections
of sciatic nerves. In osmium tetroxide-fixed teased fibers, a
conspicuous myelin thickening around the nodes of Ranvier
was apparent (Fig. 6Ba and b). In longitudinal sections, we
found that a substantial number of nodes exhibited abnormal
myelin. Redundant myelin was folded inside the original
axon (c and e) or in an outwardly directed fashion (g). Infold-
ings and outfoldings occurred focally and were not mutually
exclusive. They did not usually affect the nodes symmetri-
cally. Focally folded myelin arranged in an outward direction
contained not only myelin but also outcroppings of axons,
both continuous with the original axon–myelin structure
(f and g). This is consistent with the observation that the
number of lamellae appeared to be the same in outwardly
folded myelin as in the core-myelinated fiber (Fig. 6Ah).
Immunohistochemical analysis of Mtmr2 mutant nerves
To confirm that outfoldings in Mtmr2 mutant nerves indeed
contain axonal structures, we analyzed affected nodal
regions by immunohistochemistry. S100 delineates the cyto-
plasm of Schwann cells, and NF-L labels axons. The S100
staining allowed us to define formations consisting of a
myelinated large caliber axon and a redundant myelin loop
(Fig. 7Aa, c, h and i). Both structures are surrounded by the
S100-positive structure, indicating one Schwann cell. The
NF-L staining marks not only the large caliber axon but also
the inside of the aberrant myelin loop (Fig. 7Af and i). This
indicates that the outwardly directed focal myelin foldings
are elongations of core myelin and that axonal structures are
contained within both of them.
Figure 2. Histological analysis of sciatic nerves. Sciatic nerve cross-sections of wt (A and D), Mtmr2þ/m (B and E) and Mtmr2 m/m (C and F) mice at 2 months
of age. The gross overall morphology of heterozygous and homozygous mutant nerves appears unaltered compared with that of wt littermates (B and C
versus A). At higher magnification, redundant myelin is detectable specifically around axons of Mtmr2 m/m mice (arrowhead and arrows in F). Myelinated
fibers of Mtmr2 þ/m or wt mice are not affected (compare F with D and E). Note that the additional myelin loops and the large caliber axon in (F) marked
with an arrowhead are surrounded by continuous cytoplasm, indicating that they originate from the same Schwann cell. Scale bars for (A–C): 100 mm;
for (D–F): 25 mm.
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Redundant myelin was prominent in nodal regions, and we
therefore analyzed mutant nodes of Ranvier in more detail.
Immunohistochemical analysis of Caspr, a marker for para-
nodal axolemma, the juxtaparanodal marker Kv1.2 and
myelin staining with myelin basic protein (MBP) was used
(Fig. 7B). On teased fiber preparations, we observed nodes
of Ranvier with normal distribution of these markers
(Fig. 7Ba–d). Abnormal nodes of Ranvier were discernible
by a particularly pronounced MBP staining (g and k). The
paranodal localization of Caspr was not altered by the redun-
dant myelin (e and i). Similarly, Kv1.2 was usually still
restricted to its juxtaparanodal localization (f). Occasionally,
Figure 3. Time course analysis of sciatic nerves. Sciatic nerve cross-sections of wt (A–D) and Mtmr2 m/m (E–H) mice. The morphology was compared at the
age of 3 weeks (A and E), 2 months (B and F), 4 months (C and G) and 6 months (D and H). Three animals were analyzed per age and genotype, and repre-
sentative pictures are shown. Occasional large caliber axons affected with redundant myelin loops were detected in Mtmr2 m/m mice at 3 weeks of age (E).
Progressively more affected axons were found in older mutant mice, with both the size and the number of redundant myelin loops increasing. Scale bar for
(A–H): 25 mm.
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however, the Kv1.2-positive juxtaparanodal domain appeared
to be extended into areas of MBP-positive myelin ( j and l).
Electrophysiology of Mtmr2 mutant mice
We examined peripheral nerves of Mtmr2 mutants by
electrophysiological methods to assess the impact of the
morphological abnormalities on nerve function. Mice were
first examined at 8 months of age and again at 16 months.
In contrast to humans with CMT4B1, we found no significant
differences between mutant and wt animals with regard to
compound muscle action potential (CMAP) amplitudes (after
both proximal and distal stimulation), nerve conduction velo-
cities or F-wave latencies (Fig. 8).
DISCUSSION
We describe a novel animal model for CMT4B1. These
animals display prominent and complex myelin infoldings
and outfoldings, the pathological hallmark of this particular
form of CMT. This pathology appears to be progressive
with time, although we observed a large variability between
individual mutant mice. Surprisingly, signs of demyelination
like thinly myelinated large caliber axons or onion bulb
formation were not detected, and axonal degeneration was
only occasionally found. These structural alterations were
not reflected in disordered nerve conduction in our mutants
up to the age of 16 months.
It is informative to compare our mouse mutants with the
genotype and phenotype of the human disease CMT4B1 and
with the recently described Mtmr2 null mutant mice (13).
We will first consider the myelin pathology followed by the
electrophysiological findings.
The described myelin pathologies are largely comparable in
all three cases and thus, the Mtmr2 mutant described here and
Mtmr2 null mice will be very useful to follow up on the devel-
opment and cellular basis of this peculiar feature. The myelin
alterations might be related to the dephosphorylation of PI(3)P
and/or PI(3,5)P2 by MTMR2, which has been demonstrated
in vitro (11,30) and is likely to regulate PI(3)P or PI(3,5)P2
levels also in vivo. The specificity for the endosomal substrates
PI(3)P and PI(3,5)P2 suggests that MTMR2 may regulate
endosomal trafficking including endocytosis, vacuolar trans-
port and membrane trafficking (31–34). CMT4B1 mutations
in MTMR2, including the E276Stop mutant introduced into
the mice described in this report, lead either to a complete loss
of the phosphatase activity towards PI(3)P and PI(3,5)P2 or
to a severe reduction of the enzymatic activity (11). How
this relates to the formation of aberrant myelin foldings in
MTMR2 mutants remains to be determined. An intriguing
hypothesis has been put forward based on the association of
MTMR2 with Dlg1/SAP97 (13). This scaffolding protein
plays a role in membrane trafficking (35), and disruption of
the Dlg1/MTMR2 complex could lead to excess membrane
transport to the affected paranodes and thereby cause redun-
dant myelin formation. Alternatively or concomitantly, the
loss of phosphatase function of the MTMR2/Dlg1, or of a
conceivable MTMR2/MTMR13/Dlg1 complex, may play a
critical role in the process of myelin alteration.
Reduced NCV is a hallmark of the demyelinating neuro-
pathies, including CMT4B1 (2). Six-month-old Mtmr2 null
mice also showed reduced NCV and prolonged F-wave laten-
cies (13). Interestingly, the mutant mice reported here do
not exhibit significant electrophysiological alterations up to
the age of 16 months. This discrepancy might be related to
differences in how the mutant mice were generated (null
mutant versus introduction of a stop codon at position 276).
Figure 4. Quantification of myelinated fibers and redundant myelin loops.
(A) Quantification of fibers exhibiting redundant myelin loops at 3 weeks and
6 months of age. For each stage, the pectineus nerve was isolated from three
mice per genotype. Ten semithin sections per nerve were used for quantification.
The mean value per mouse is shown as triangles for wt and as circles for Mtmr2
m/m mice. The number of affected myelinated fibers tends to increase in Mtmr2
m/m mice during aging (note different scales for the two graphs), although there
is great variation among different mice. (B) Relation between axon diameter and
myelin thickness of 3-week- and 6-month-old mice. For each age, the sciatic
nerves of three animals per genotype were analyzed. Myelin thickness was
determined and plotted as a function of the corresponding axon diameter.
Each line represents the trend line for one mouse. Slope and intercept did not
differ significantly between wt and Mtmr2 m/m mice at either age.
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Alternatively, mouse strain differences may be responsible for
these seemingly contradictory observations.
Several other observations are also subtly different in
Mtmr2 null mice versus the mutants described here. First,
Mtmr2 null mice have not been obtained with a Mendelian
distribution (13), whereas this was the case for our mutants.
Secondly, a testis phenotype has been described in Mtmr2
null mice and is consistent with an earlier described azoosper-
mia in an isolated CMT4B1 patient (14) and with the testis
phenotype of Mtmr5 null mice (36) [MTMR5 is a binding
partner of MTMR2 (21)]. In our case, this pathology was
highly variable between individual males (data not shown).
On the basis of these findings, together with the observed
variability of the nerve pathology, we favor the hypothesis
that strong modifier genes are involved in the modulation of
the phenotype, varying either within the mixed background
of the individual mutant lines or between the two disease
models. These two mouse models may thus offer an opportu-
nity to analyze the potential role of such modifier genes in a
well-defined disease. To approach this important question sys-
tematically, it will be necessary to produce congenic strains,
followed by a detailed comparative analysis.
Both the Mtmr2 null mice and our mutants are less severely
affected than might have been expected from the symptomol-
ogy of CMT4B1. It is a general observation that in mouse
models of demyelinating forms of CMT, the mutants are
less affected than are humans suffering from the corresponding
clinical condition (3). Although the Mtmr2 null mice exhibited
electrophysiological abnormalities, against the background
of the human disease they were rather mild. Moreover, the
reduction of F-wave conduction was disproportionately
minor when compared with the reported NCV of more distal
nerve segments. The marked reduction of NCV observed in
CMT4B patients may be related to different mutations or to
the role of important modifier genes in humans. Demyelina-
tion and secondary axonal loss might also be more pronounced
because of the much longer nerves in humans, with impaired
axonal transport potentially playing an important role (2).
The phenotype may also increase in severity with age, and
the lifetime of a mouse may not be long enough to allow
full development of the disease. Although we have observed a
progressive development of myelin abnormalities, both quali-
tatively and quantitatively, we have not found indications for a
neurological worsening in the mutants up to 16 months of age.
Functional redundancy and compensation by other myotubu-
larins may be involved, although quantitative RT–PCR analy-
sis of mutant nerves of young adult animals has not revealed
consistent alterations in the level of either the closely related
family members MTM and MTMR1 or the MTMR2-binding
partners MTMR5 and MTMR13 (data not shown).
In conclusion, we have generated a new animal model for
CMT4B1, mimicking a mutation found in human patients
with typical CMT4B1. The effects on myelin structure were
similar to those seen in humans, although the clinical impact
was not so severe. There were obvious differences in compari-
son to the previously described null mutant mouse with regard
to electrophysiological parameters, frequency of homozygous
mutants among offspring and variability of the phenotype.
Together with the null mutant, our mutant should therefore
prove valuable for examining the consequences of different
Figure 5. Histological analysis of distal and proximal PNS nerves. Cross-sections of proximal (A: ventral roots, B: dorsal roots) and distal (C: gluteus nerve,
D: saphenous nerve) nerve segments of Mtmr2 m/m mice at 6 months of age. Myelin infoldings and outfoldings were rarely found in proximal areas, whereas
they occur often in distal nerves. Scale bar for (A–D): 25 mm
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Mtmr2 mutations in terms of physiological disturbances and
genetic background.
MATERIALS AND METHODS
Generation of the Mtmr2 mutant allele
Vector construction: a mouse genomic clone including the
Mtmr2 gene (BAC clone number 26987, Incyte) served as
starting point. The short arm was generated by PCR using
the BAC clone as template, with forward primer SAfo:
50-ATA AGA ATG CGG CCG CGG CGC GCC CTG AGG
GCT CCT GTG AGA C-30, with NotI and AscI restriction
sites introduced for cloning and vector linearization at the
50 end, and reverse primer SAba: 50-GAT CTC TAG ATC
ACT ATT AAG GAT GAA TCC AGG A-30, with an XbaI
restriction sequence at the 30 end for cloning. The PCR frag-
ment was cloned via NotI–XbaI into the IRES-lacZ-tk-neo
cassette-vector backbone (37). The long arm was generated
by EcoRI digestion of the BAC clone and isolation of
a 6.5 kb fragment containing exons 13–15 of Mtmr2. This
EcoRI fragment was subcloned into the pGEM-T-Easy
vector (Promega). Using the restriction sites XhoI and SalI
of this vector, the long arm was inserted into the short
arm-IRES-lacZ-tk-neo cassette backbone. The final construct
was linearized, electroporated into TC-1 ES cells (129SvS6/
SvEvTac), and clones were selected with G418. Growing
clones were analyzed first by PCR. Eleven positive clones
were further analyzed by Southern blotting for correct
and single integration. Two clones were used for blastocyst
Figure 6. Focally folded myelin in Mtmr2 m/m sciatic nerve. (A) Electron microscopic analysis of sciatic nerves derived from 6-month-old Mtmr2 m/m mice.
The figure shows a collection of the different types of focally folded myelin. Single or multiple abundant myelin loops aligned around the original myelinated
axon are the most frequent forms of abnormal myelin (a). Redundant myelin can appear as elongated loops arranged sausage-like around the axon (b). Comma-
like extensions of the original myelinated fibers (c) are more frequently detectable in Mtmr2 m/m mice compared with wt. They can reach sizes sufficient to
surround other aberrant myelin loops (d) or the original axon (data not shown). Focal abundant myelin loops can also be found inside a myelinated axon as
single or multiple loops nested into each other (e). Interleaved myelin loops can also be observed (f). Rarely, degenerating axon–myelin units (g) are detectable.
The number of lamella is the same in the outfoldings compared to the core myelin (h). (B) Teased fiber preparations of 9-month-old wt (a) and Mtmr2 m/m (b)
sciatic nerves revealed an increased number of nodes of Ranvier that are affected with redundant myelin. A collection of affected nodes are shown in longitudinal
sections in (c–e). The additional myelin can be folded inwards (black arrow in c and e) or outwards (white arrow in d and e). Note that the nodes are not affected
symmetrically. Aberrant myelin foldings are extensions of the original axon/myelin unit (f and g). A schematic drawing of the situation in (g) is shown in the
right part of (h) for illustration, together with a schema for a normal node for comparison on the left. Scale bars for (a and b): 5 mm; for (c–e): 6 mm.
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injection (Institute for Laboratory Animal Science, University
of Zurich) to obtain chimeric mice. These were crossed with
wt C57Bl/6 mice. Both ES cell clones resulted in mouse
lines (sb65 and sb59). These produced offspring at the
expected frequencies (line sb65: wt: 25.6%; heterozygous:
48.8%; homozygous: 25.6% with a total of 207 animals; line
sb59: wt: 27%; heterozygous: 48.6%; homozygous: 24.3%
with a total of 37 animals analyzed).
Genotyping PCR
Primers specific for the wt allele are W1: 50-GTG TGT ATT
TAC TAC TCT TTC TC-30 and W2: 50-GCA GTT TGG
TTA GAT ATG TGA CCT G-30. Primers for the detection
of the mutated allele are K1: 50-GCA TGC ATA CCT ATC
TCT ATA TAG C-30 and K2: 50-AAC GCA CGG GTG
TTG GGT CG-30.
Figure 7. Immunohistochemical analysis of Mtmr2 m/m sciatic nerves. (A) Colocalization study on sciatic nerves of 9-month-old Mtmr2 m/m mice using
S100 as a Schwann cell marker (a–c) and NF-L as an axonal marker (d–f). Overlays are shown in (g–i). The lower panels represent single myelinated
fibers indicated in the overviews. A normal fiber is shown in (b, e and h). The Schwann cell in c surrounds not only a single ring of myelin (remains black
in this staining) with the corresponding axon (marked with NF-L in f), but also an additional loop (arrow in c). Remarkably, this redundant myelin surrounds
an axonal, NF-L positive structure (arrow in f). Scale bar for (a, d and g): 20 mm. (B) Analysis of sciatic nerve teased fiber preparation from 9-month-old Mtmr2
m/m mice. Localization of Caspr (a, e and i), Kv1.2 (b, f and j) and MBP (c, g and k) was assessed to determine the influence of aberrant myelin foldings on the
organization of the node of Ranvier. In (a–d), a node without myelin aberration shows normal localization of Caspr, Kv1.2 and MBP. A nodal region affected
with an outfolding is shown in (e–h). An outfolding is present above the right side of the node (arrows) but does not change the localization of Caspr and Kv1.2.
The node in (i-l) is affected by outfoldings on both sides of the node. Here, staining for the marker Kv1.2 extends into the outfolding (asterisks in j and l). Scale
bars (a–l): 1 mm.
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Histological analysis
For semithin sections and electron microscopy, mice of differ-
ent ages were anesthetized with pentobarbital (Eutha77;
Essex) and perfused with 0.1 M phosphate buffer pH 7.2
containing 4% PFA and 3% glutaraldehyde. Samples were
post-fixed overnight in the same fixative at 48C. Samples
were then washed in phosphate buffer, treated with 2%
OsO4 overnight at 48C, dehydrated in an ascending acetone
series, infiltrated with Spurr and incubated at 608C for
polymerization. Semithin sections (0.5 mm) were stained
with 0.1% Toluidine blue. Electron microscopic pictures
were taken digitally with a Philips Fei Morgani using
ANALYSIS software (Soft Imaging System, Mu¨nster,
Germany). Pictures were processed in Photoshop.
Teased OsO4-fixed fibers were obtained by separating single
fibers of sciatic nerves after the ascending acetone series and
infiltration with Spurr.
For immunohistochemistry, isolated nerves were frozen in
OCT and cut to 7 mm sections, which were then fixed with
4% PFA. For teased fibers, nerves were fixed in 4% PFA for
30 min at room temperature, and fibers then separated in
PBS. Teased fibers were permeabilized in ice-cold acetone
prior to the blocking step for 10 min. Both sections and
teased fibers were blocked with 1% BSA/0.3% Triton
X-100/10% goat serum. Primary antibodies were diluted in
blocking solution and incubated overnight at 48C [rabbit poly-
clonal anti-S100 1:300 (DAKO), mouse monoclonal anti-NF-
light chain 1:40 (Sigma), rabbit polyclonal anti-Caspr 1:500
(a kind gift from Drs L. Pedraza and D. Colman, Montreal),
mouse monoclonal anti-Kv1.2 1:50 (Upstate Biotechnology),
rat monoclonal anti-MBP 1:50 (Serotec)]. Secondary anti-
bodies were incubated in blocking solution for 1 h at room
temperature [goat anti-rabbit Cy3 1:300; goat anti-mouse
Cy2 1:200; goat anti-rat Cy5 1:300 (Jackson Immuno
Research Laboratories)]. Specimens were mounted in Citiflour
(Canterbury, UK) and analyzed on a Zeiss Axioplan micro-
scope. Pictures were taken with a Zeiss Axiocam and pro-
cessed in Photoshop.
G-ratios
Three animals per genotype were analyzed at each age
(3 weeks and 6 months). Sciatic nerves were processed to
0.5 mm semithin sections and stained with Toluidine blue.
The axon caliber and the myelin sheath thickness were deter-
mined using the ANALYSIS software. We evaluated only
fibers with normally compacted myelin (extending over the
entire thickness of the sheath) and excluded fibers with promi-
nent myelin foldings. Myelin thickness of sciatic nerve fibers
was plotted as a function of the corresponding axon diameter.
Statistical analysis for this and the tests below was performed
using Student’s t-test.
Rotarod test
Mice were placed on a Rotarod apparatus (TSE Systems,
Germany), and the rod was accelerated from 4 to 40 r.p.m.
Time spent on the rotating rod was measured. The trial was
stopped after 10 min. A mouse not running but spinning on
the rotating rod two or more times was considered to be
exhausted, and the trial was stopped.
Grip strength analysis
Mutant and control mice were tested five consecutive times.
Each time mice were allowed to grab a movable metal grid.
They are then lifted by the tail and slightly pulled back
for 1 min. The peak weight that the mouse could hold was
recorded (in grams). The maximum value was then divided
by the body weight of the mouse.
Nerve conduction studies
Motor nerve conduction of sciatic nerves in anesthetized
8- and 16-month-old wt and mutant mice (n¼6 in each
group) was investigated by a robust technique as described
previously (5). After supramaximal stimulation of the tibial
nerve at the ankle and stimulation of the sciatic notch, the
CMAPs were recorded with steel needle electrodes in the
foot muscles.
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